Justin Zelin
Stock Analyst at BTIG
(1.63)
# 3,490
Out of 5,143 analysts
44
Total ratings
27.91%
Success rate
-8.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $25.20 | +78.57% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $20.79 | +169.36% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $25.52 | +95.92% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.18 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.79 | +346.93% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $36.20 | +71.27% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.74 | +977.59% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $34.09 | +266.68% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.57 | +345.86% | 3 | Sep 22, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $6.69 | +198.95% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $7.34 | -18.26% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $27.03 | +55.38% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.20 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.07 | +74,666.36% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $35.03 | +159.78% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $8.40 | +1,804.76% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.18 | +633.94% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $19.34 | +365.36% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.09 | +241.03% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $62.23 | -75.09% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $0.99 | +912.56% | 3 | Nov 16, 2022 |
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $25.20
Upside: +78.57%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $20.79
Upside: +169.36%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $25.52
Upside: +95.92%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $36.20
Upside: +71.27%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.74
Upside: +977.59%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $34.09
Upside: +266.68%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.57
Upside: +345.86%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $6.69
Upside: +198.95%
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $7.34
Upside: -18.26%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $27.03
Upside: +55.38%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.20
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.07
Upside: +74,666.36%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $35.03
Upside: +159.78%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $8.40
Upside: +1,804.76%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.18
Upside: +633.94%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $19.34
Upside: +365.36%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.09
Upside: +241.03%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $62.23
Upside: -75.09%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $0.99
Upside: +912.56%